GlaxoSmithKline plc has signed a deal with CureVac to develop and commercialize up to five mRNA-based vaccines and monoclonal antibodies targeting infectious diseases, paying £104m ($130m) upfront and acquiring a stake in the company worth £130m ($163m).
CureVac also stands to receive development and regulatory milestone payments of up to £277m (€320m), commercial milestone payments of up...






